Nuclear receptors are also referred to PPARs, short for proliferator-activated receptors. Their activity is attributed to antitumor effects. CBD activates PPARs, which are found on the surface of the cell’s nucleus. When the PPAR-gamma receptor is stimulated, it triggers an antiproliferative effect that has been shown to cause cancer to regress in lung cancer cell families .
CBD is known to have a tremendous number of medicinal properties, but because the field of marijuana research is in its infancy, we still need more studies to examine the full potential of the plant’s compounds.
When the orphan receptor shows signs of constant overactivity, it may eventually cause osteoporosis and contribute to the multiplication and migration of tumor cells. CBD inhibits GPR55 signaling, which is linked to the ability of this cannabinoid to stop the growth of cancer.
Medical Benefits of CBD For the Brain
While most of the research available today has put its focus on understanding the relationship between humans and THC, CBD on the brain has been recently shown to have great potential with regard to its medical versatility. Once we fully understand all the properties of hemp and marijuana, we will be able to unlock its full power and use it in a way that could benefit us even more than it does now.
The orphan receptor has got its name because scientists are still unsure if it belongs to a larger receptor family. Also called GPR55 , the orphan receptor is responsible for regulating blood pressure, bone density, and bone reabsorption .
Cannabidiol acts through various molecular pathways , which explains the neurological effects of CBD oil. Although CBD doesn’t tap into two of the cannabinoid receptors, it stimulates the activity of the endocannabinoid system through several different receptor-independent routes . CBD also strengthens and inhibits the binding action of certain protein-coupled receptors.
On top of that, the topical use of CBD has been shown by numerous studies to improve joint mobility and speed up the healing process after an injury. Many professional athletes use CBD to fight muscle inflammation and other pain-related issues .
The Los Angeles-based Humble Flower Co. sells its lotions, creams, and massage oils at select California marijuana dispensaries only, but several other companies, such as Blue Ridge Hemp, sell their goods online and in stores across the country. Last summer, the trendy vegan fast-food chain By Chloe added a line of CBD-infused products to its menus in New York and called the new offering “Feelz by Chloe.”
Taken as a syrup and made by the British-based drugmaker GW Pharmaceuticals, the drug is designed to treat seizures linked with two rare forms of childhood epilepsy. The drug is made with CBD harvested from marijuana plants.
CBD has some limited — and very specific — clinical uses. But it's still unclear whether it could have health benefits for most people.
“We will need to carefully evaluate how all these pieces fit together in terms of how consumers might access cannabis products,” Sharpless said Friday.
In June 2018, a prescription CBD-based epilepsy drug called Epidiolex became the first of its kind to be approved by the federal government.
Under Sharpless, the agency will likely crack down on CBD when it comes to 3 main areas: 1) when products make health claims, 2) when CBD-infused food products are sold across state lines, and 3) when the products are marketed as dietary supplements.
Keywords: Cannabis (marijuana); cannabidiol; delta9-tetrahydrocannabinol; functional MRI; neuroimaging.
Copyright © 2021 Batalla, Bos, Postma and Bossong.
Conflict of interest statement
Background: Accumulating evidence suggests that the non-intoxicating cannabinoid compound cannabidiol (CBD) may have antipsychotic and anxiolytic properties, and thus may be a promising new agent in the treatment of psychotic and anxiety disorders. However, the neurobiological substrates underlying the potential therapeutic effects of CBD are still unclear. The aim of this systematic review is to provide a detailed and up-to-date systematic literature overview of neuroimaging studies that investigated the acute impact of CBD on human brain function. Methods: Papers published until May 2020 were included from PubMed following a comprehensive search strategy and pre-determined set of criteria for article selection. We included studies that examined the effects of CBD on brain function of healthy volunteers and individuals diagnosed with a psychiatric disorder, comprising both the effects of CBD alone as well as in direct comparison to those induced by ∆9-tetrahydrocannabinol (THC), the main psychoactive component of Cannabis. Results: One-ninety four studies were identified, of which 17 met inclusion criteria. All studies investigated the acute effects of CBD on brain function during resting state or in the context of cognitive tasks. In healthy volunteers, acute CBD enhanced fronto-striatal resting state connectivity, both compared to placebo and THC. Furthermore, CBD modulated brain activity and had opposite effects when compared to THC following task-specific patterns during various cognitive paradigms, such as emotional processing (fronto-temporal), verbal memory (fronto-striatal), response inhibition (fronto-limbic-striatal), and auditory/visual processing (temporo-occipital). In individuals at clinical high risk for psychosis and patients with established psychosis, acute CBD showed intermediate brain activity compared to placebo and healthy controls during cognitive task performance. CBD modulated resting limbic activity in subjects with anxiety and metabolite levels in patients with autism spectrum disorders. Conclusion: Neuroimaging studies have shown that acute CBD induces significant alterations in brain activity and connectivity patterns during resting state and performance of cognitive tasks in both healthy volunteers and patients with a psychiatric disorder. This included modulation of functional networks relevant for psychiatric disorders, possibly reflecting CBD’s therapeutic effects. Future studies should consider replication of findings and enlarge the inclusion of psychiatric patients, combining longer-term CBD treatment with neuroimaging assessments.
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.